Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01835925 · ClinicalTrials.gov registry record
Rectal Cancer Consortium
A clinical trial of Rectal Cancer, sponsored by Brown University.
- Completed
- Registry status
- 12
- Enrollment target
- 2
- Study locations
NCT01835925: Completed study of Rectal Cancer, sponsored by Brown University.
NCT01835925 is a study of Rectal Cancer that has completed, run by Brown University. The registered enrollment target is 12 participants, below the 3,167-participant average among 70 other Rectal Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01835925, a study of Rectal Cancer, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to study which genes are abnormal in rectal cancer and see if this predicts how well chemotherapy and radiation will reduce the size of cancer and whether cancer recurs after surgery.
Conditions Studied
Interventions
- GENETIC Tissue specimen
Study Locations (2)
Rhode Island
- Rhode Island Hospital - Providence
- The Miriam Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-07 |
| Est. Completion | 2014-04 |
What the finished NCT01835925 record still lists
NCT01835925 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 3,167-participant average among 70 other Rectal Cancer trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tissue specimen is the first listed.
NCT01835925 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT01835925 about?
NCT01835925 is a clinical study titled "Rectal Cancer Consortium". The purpose of this study is to study which genes are abnormal in rectal cancer and see if this predicts how well chemotherapy and radiation will reduce the size of cancer and whether cancer recurs after surgery.
What is the current status of trial NCT01835925?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2013-07. Estimated completion is 2014-04.
What conditions does trial NCT01835925 study?
This clinical trial studies the following conditions: Rectal Cancer.
What interventions are being tested in trial NCT01835925?
The interventions under investigation include: Tissue specimen (GENETIC).
Who is sponsoring clinical trial NCT01835925?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01835925 being conducted?
This trial has 2 study locations across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01835925's enrollment target sits among peer trials
12 69th of 70 higher than 2 of 70 other Rectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
RECRUITING · Phase 1
-
Exosomes in Rectal Cancer
RECRUITING
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
RECRUITING · Phase 2
-
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
RECRUITING · NA
-
Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia